Home

MacroGenics, Inc. - Common Stock (MGNX)

2.1800
+0.1300 (6.34%)

Macrogenics is a biotechnology company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and other serious diseases

The company’s research and development efforts aim to harness the power of the immune system to fight tumors, utilizing advanced technologies to engineer molecules that can specifically target and modulate tumor-associated antigens. Macrogenics collaborates with various partners to advance its pipeline of proprietary and partnered programs, including therapies that are currently undergoing clinical trials, with the goal of providing new treatment options for patients with unmet medical needs.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close2.050
Open2.050
Bid2.150
Ask2.210
Day's Range2.030 - 2.200
52 Week Range2.040 - 19.54
Volume520,837
Market Cap133.21M
PE Ratio (TTM)-1.380
EPS (TTM)-1.6
Dividend & YieldN/A (N/A)
1 Month Average Volume547,221

News & Press Releases

MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET
By MacroGenics, Inc. · Via GlobeNewswire · March 6, 2025
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March:
By MacroGenics, Inc. · Via GlobeNewswire · February 27, 2025
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Macrogenics, Inc. (NASDAQ: MGNX) on behalf of long-term stockholders following a class action complaint that was filed against MGNX on July 26, 2024 with a Class Period from March 7, 2024 to May 9, 2024. Our investigation concerns whether the board of directors of MGNX have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · December 10, 2024
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insightsbenzinga.com
Via Benzinga · November 7, 2024
Macrogenics Earnings Previewbenzinga.com
Via Benzinga · November 4, 2024
Macrogenics Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)benzinga.com
Via Benzinga · September 18, 2024
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
By MacroGenics, Inc. · Via GlobeNewswire · December 2, 2024
MacroGenics (MGNX) Q3 2024 Earnings Call Transcriptfool.com
MGNX earnings call for the period ending September 30, 2024.
Via The Motley Fool · November 5, 2024
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
By MacroGenics, Inc. · Via GlobeNewswire · November 6, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 6, 2024
MacroGenics Announces Leadership Transition
ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.
By MacroGenics, Inc. · Via GlobeNewswire · October 30, 2024
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET.
By MacroGenics, Inc. · Via GlobeNewswire · October 29, 2024
MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain management, announced today that they have entered into an agreement in which TerSera will acquire global rights to MARGENZA® (margetuximab-cmkb).
By TerSera Therapeutics LLC · Via Business Wire · October 22, 2024
MGNX Investors Have Opportunity to Join MacroGenics, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MacroGenics, Inc. (“MacroGenics” or “the Company”) (NASDAQ: MGNX) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · September 24, 2024
MGNX DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MacroGenics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 24 Deadline in Securities Class Action – MGNX
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · September 23, 2024
MGNX Investors Have Opportunity to Lead MacroGenics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MacroGenics, Inc. (“MacroGenics” or “the Company”) (NASDAQ: MGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By The Schall Law Firm · Via Business Wire · September 23, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics and Vicor and Encourages Investors to Contact the Firm
NEW YORK, Sept. 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of MacroGenics, Inc. (NASDAQ: MGNX) and Vicor Corporation (NASDAQ: VICR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · September 21, 2024
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MacroGenics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MacroGenics To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · September 19, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MacroGenics and Vicor and Encourages Investors to Contact the Firm
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of MacroGenics, Inc. (NASDAQ: MGNX) and Vicor Corporation (NASDAQ: VICR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · September 17, 2024
MGNX Deadline: Rosen Law Firm Urges MacroGenics, Inc. (NASDAQ: MGNX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024. MacroGenics describes itself as a “biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.”
By The Rosen Law Firm, P.A. · Via Business Wire · September 17, 2024
MACROGENICS, INC. (NASDAQ: MGNX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds MacroGenics, Inc. Investors of Upcoming Deadline
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · September 16, 2024
Investor Reminder (MGNX):  Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc.  Investors of September 24, 2024 Deadline
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the “Class Period”). The lead plaintiff deadline is September 24, 2024.
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · September 16, 2024
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
ROCKVILLE, MD, Sept. 15, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, for patients with metastatic castration-resistant prostate cancer (mCRPC). The data were featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024.
By MacroGenics, Inc. · Via GlobeNewswire · September 15, 2024
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CAE, MacroGenics, Vicor, and American Airlines and Encourages Investors to Contact the Firm
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CAE Inc. (NYSE: CAE), MacroGenics, Inc. (NASDAQ: MGNX), Vicor Corporation (NASDAQ: VICR), and American Airlines Group Inc. (NASDAQ: AAL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · September 13, 2024
Faruqi & Faruqi Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 - MGNX
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MacroGenics To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · September 13, 2024